Administration of Enfortumab Vedotin after Immune-Checkpoint Inhibitor and the Prognosis in Japanese Metastatic Urothelial Carcinoma: A Large Database Study on Enfortumab Vedotin in Metastatic Urothelial Carcinoma.

Takashi KawaharaAkihito HasizumeKoichi UemuraKatsuya YamaguchiHiroki ItoTeppei TakeshimaHisashi HasumiJun-Ichi TeranishiKimito OusakaKazuhide MakiyamaHiroji Uemura

Published in: Cancers (2023)

Enfortumab vedotin prolonged the overall survival for Japanese advanced or metastatic urothelial carcinoma patients compared to paclitaxel or docetaxel after pembrolizumab treatment.

Keyphrases

squamous cell carcinoma
small cell lung cancer
hodgkin lymphoma
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
patient reported outcomes
radiation therapy
adverse drug